

Pharmacotherapy of Schizophrenia: The Past, Present and Future

Shahin Akhondzadeh*

Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract: Traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a chronic course and an unfavorable outcome. Throughout history, there has been incidence of schizophrenia, roughly one percent of the population, consistently, in every culture. It is generally acknowledged that schizophrenia has multifactorial etiology, with multiple susceptibility genes interacting with environmental insults to yield a range of phenotypes in the schizophrenia spectrum. The discovery of antipsychotics in the 1950s revolutionized the treatment of schizophrenia and focused on the positive symptoms. By the 1960s, however, it became obvious that the reduction in positive symptoms did not lead to recovery from schizophrenia and did not improve the functional outcome significantly. The advent of the novel antipsychotics during the last 15 years represents a significant improvement over the effectiveness of conventional antipsychotics. However, these agents are not a magic bullet and are associated with their own attendant treatment complications, such as weight gain, diabetes, hyperprolactinemia, and QTc prolongation. Nevertheless, at this point, they seem to be more effective and safer than conventional antipsychotics. Moreover, advances in the treatment of schizophrenia have been and continue to be urgently needed.

INTRODUCTION

Schizophrenia is a devastating neurobiologic disorder that typically strikes the brain function of adolescents and young adults, occurring in about 1 of every 100 people worldwide. The direct costs of schizophrenia accounted for 2.5% of US health expenditures. Despite these expenditures, up to half of all people with schizophrenia at any point in time are not receiving active psychiatric care, and at least 15% to 20% of people suffering from the disorder will never receive any psychiatric treatment. Moreover, although the financial costs of schizophrenia can be calculated, the cost of unrealized human potential and lost dignity associated with the disease are beyond computation. For all of these reasons, advances in the treatment of schizophrenia have been and continue to be urgently needed [1-7].

WHAT IS SCHIZOPHRENIA?

Criteria for diagnosis of schizophrenia, defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) [8], dictate that at some stage of the illness, patients experience at least two of five types of characteristic symptoms. The four positive symptoms -so called because they indicate the product of an abnormal disease process - include delusions, hallucinations, grossly disorganized or catatonic behavior and disorganized speech, and are considered to be psychotic since they are inconsistent with the experiences of normal humans. Symptoms such as withdrawal, anhedonia, anergia and affective flattening, are termed negative because they indicate a deficit of normal function and are not psychotic (Table 1). However, the onset, time course and nature of the disturbances in emotion, personality, cognition and motor activity exhibited by patients with schizophrenia vary widely [9, 10].

BACKGROUND AND HISTORICAL PERSPECTIVE

The first consideration of pharmacotherapy for schizophrenia came with the use of Rauwolfia alkaloids, first

considered in 1931, and gaining considerable interest by the early 1950s. Toxic substances, e.g. insulin, metrazol, were used to induce shock treatments. Prior to the inception of modern pharmacotherapy, e.g. tranquilisers, there was experimentation with hashish and cocaine [7]. LSD was synthesized in 1943. Its psychedelic effects were later used for recreational purposes, as well as for investigating the human psyche. Some psychotherapeutic benefit is proposed from LSD [6]. Research, although highly restricted, continues. LSD came into disrepute when it was proposed as a chemical warfare agent, and when it was used by the US intelligence community in efforts to brain-wash subjects through a technique called "Psychic Driving". Psychic driving was tested on unsuspecting hospitalized mentally ill people without their consent [7].

From the introduction of conventional antipsychotics that sparked massive deinstitutionalization in the 1960s to the reintroduction of clozapine in 1988 and the discovery of atypical antipsychotics, the struggle to effectively treat schizophrenia and related disorders continues. The introduction of chlorpromazine (CPZ) in 1952 was an indisputable advance in psychiatry. CPZ's efficacy in treating the positive symptoms of schizophrenia is well established. Over the next 20 years, about 40 similar medications were introduced world-wide in to the market, comprising a class of antipsychotic medications now termed "typicals." All typicals studied have similar mechanisms of action and comparable efficacy. The choice of medication among the typicals thus is largely based on their relative side effect profile [4, 7]. The two most troublesome side effects are extrapyramidal side effects (EPSEs) and tardive dyskinesia. (TD). The debilitating symptoms of EPSEs are now known to occur in 75% to 90% of patients taking typicals. The annual cumulative incidence of TD in young, healthy adults taking typicals is 4% to 5%, and the risk increases with age and duration of exposure to the medication. Further, cases of TD were recognized as being disfiguring, irreversible, and potentially fatal as early as the late 1960s [7]. Moreover, studies began to emerge suggesting that much of the functional disability associated

*Address correspondence to this author at the No: 29, 39th Street, Gisha Street, Tehran 14479, Iran; Tel: 98-21-55412222; Fax: +98-21-55419113; E.mail: s.akhond@neda.net

Table 1. Clinical Features of Schizophrenia

| | |
|---|---|
| <p>Positive symptoms (function distorted)</p> <ul style="list-style-type: none"> • Hallucinations (perception) • Delusions (inferential thinking) • Disorganized speech • Bizarre behavior | <p>These are essentially disordered versions of the normal brain functions of thinking, perceiving, formation of ideas and sense of self. Patients with thought disorder may present with complaints of poor concentration or of their mind being blocked or emptied: a patient stopping in a perplexed fashion while in mid-speech and the interviewer having difficulty in following the speech are typical signs</p> |
| <p>Negative symptoms (functions diminished)</p> <ul style="list-style-type: none"> • Alogia (fluency of speech/thought) • Affective blunting (emotional expression) • Avolition (volition and drive) • Anhedonia/asociality (ability to feel pleasure, experience emotional attachments, and/or form relationships with others) • Attention impairment (focusing attention) | <p>These involve loss of personal abilities such as initiative, interest in others and anhedonia. Blunted or fatuous emotions (flat affect) limited speech and prolonged periods of inactivity are typical behaviors.</p> |

with schizophrenia is associated with negative symptoms and cognitive deficits, for which the typicals showed little potential treatment efficacy [7]. After a hiatus of almost 15 years, clozapine was reintroduced in North America following the landmark trial by Kane and others in 1988 comparing clozapine with CPZ in treatment-refractory schizophrenia. It was the first antipsychotic shown to be more effective than haloperidol and CPZ for positive symptoms and, incidentally, negative symptoms and also offered a better side effect profile free of EPSEs and TD. With its unique pharmacology and relatively low D₂ antagonism and more potent 5-HT₂ antagonism, clozapine became the prototype atypical antipsychotic. The confirmation of clozapine's superior efficacy in treating patients with schizophrenia compared with the typical antipsychotics, triggered further pharmaceutical industry research for more similarly effective newer medications [4, 7].

ETIOLOGY OF SCHIZOPHRENIA

It is unclear whether schizophrenia is an old or modern illness. Ancient records (first century) describe a type of insanity in persons labeled either "gifted" or "cursed" depending on religious criteria, and early treatment often involved care by the family or church, but some early hypotheses considered the possibility that brain damage or malformation could account for these behaviors. Some authorities argue that no descriptions of true schizophrenia were published until more modern times. The term schizophrenia (splitting of the mind) was introduced in 1911 and is meant to convey a splitting of usually integrated psychic functions [4, 11-13].

The onset of symptoms differentiable from non affected twins tends to cluster around certain ages (0–5 and 13–17 y), with a predominance of boys in the younger range and equal number of males and females in the older age group [7]. There is no clear difference in occurrence of schizophrenia among different cultures. Some computed tomography and magnetic resonance imaging studies suggest possible increased cerebral ventricular size, decreased brain mass, or decreased left temporal lobe size in certain subsets of schizophrenics, and some neurodevelopment models implicate possible abnormal brain circuit maturation during the

second trimester of gestation. Environmental factors such as viruses, pollution, trauma, dietary deficiencies, toxins, infections, or insecticides have been invoked as causative. Most experts believe that schizophrenia results from a complicated interplay of environmental, biologic, psychological, cultural, and genetic factors [4, 11-13].

BIOCHEMICAL BASIS

Dopamine Hypothesis

Scientists have noted the role of dopamine in schizophrenia since they uncovered the chemical reactions behind the first antipsychotics [14]. However, the exact nature of its role has long been - and remains in - dispute. The first model of the role of dopamine in schizophrenia was the dopamine hyperactivity hypothesis. This asserts that hyperactivity of the brain's dopaminergic systems is directly responsible for the symptoms of schizophrenia [15-17]. In the period since its inception, this hypothesis has been accepted, studied and supported by neuroscientists. One supportive observation involves the actions of drugs that enhance the activity of dopaminergic systems. Amphetamine is one such drug; when introduced in chronic amounts, amphetamines can induce symptoms virtually identical to those of a paranoid psychosis. The dopamine hypothesis was the first durable biological framework for understanding the etiology and treatment of schizophrenia [14, 15]; however, it failed to explain many aspects of schizophrenia, such as negative symptoms, cognitive deficits and other neurochemical and pathological findings (Table 1). Interest in dopamine interactions with other neurotransmitter systems has contributed to the development of novel antipsychotics with better clinical efficacy [14, 15-17]. In addition, another weakness of the dopamine hypothesis involves the time course of the clinical effects of antipsychotics. While neuroleptics block D₂ receptors shortly after crossing the blood-brain barrier, their antipsychotic effects do not reach a clinically significant level until, on average, one to two weeks later. In addition, antipsychotics neither cure the illness, nor stop the relapse of symptoms completely, and about 30% of patients are refractory to treatment with dopamine blockers. In this regard, the atypical antipsychotics, which are less specific blockers of dopamine, may be

superior to haloperidol and result in fewer extrapyramidal symptoms [14, 15-17]. The major limitations of conventional antipsychotic drugs are their marked tendency to cause extrapyramidal symptoms, poor efficacy against negative schizophrenic symptoms, inability to reverse or prevent the development of the cognitive impairment of schizophrenia and inability to permit a normal level of psychosexual and work function. These factors lead to a poor quality of life even for patients whose positive and disorganized symptoms respond to neuroleptic treatment [18-23]. In the past 20 years, several basic research findings have provided hypotheses about physiopathology of schizophrenia. This research, which spans many different disciplines, includes studies of the receptor pharmacology of neuroleptics at dopamine, serotonin, glutamate, purinergic and muscarinic receptors, electrophysiological studies with rats treated chronically with drugs, and molecular biological studies measuring the expression of immediate early genes [18-24].

Serotonin Hypothesis

Serotonin (5-HT) is an essential neurotransmitter synthesized from dietary tryptophan. A possible role of 5-HT in schizophrenia was first recognized in the 1950s when researchers noticed its similarity to lysergic acid diethylamide (LSD) [25]. LSD competes for and occupies 5-HT receptor sites with very high potency, resulting in psychosis-like symptoms. These observations eventually led to a hyper-serotonin hypothesis for schizophrenia. Like dopamine, evidence for the actions of 5-HT in schizophrenia lies in observations of brain-behavior relations, neurotransmitter systems, drug mechanism and postmortem studies. Some studies have found elevated 5-HT levels in blood platelets. These studies indicate that CSF levels of both 5-HT and its primary metabolite 5-hydroxyindolacetic acid are more reflective of brain 5-HT transmission [26, 27]. However, reports of CSF levels are quite conflicting. The strongest evidence of the role of 5-HT in schizophrenia, by far, is the mechanism of atypical antipsychotic drugs like clozapine. These drugs, which have provided dramatic improvements in patients that were resistant to other medications, interestingly, show a weak direct dopaminergic antagonist effect. They are also very selective of where and on which receptors they act. One could conclude, therefore, that the principal mechanism of symptom relief with atypical antipsychotics is from something other than dopamine antagonism [28-31]. This mechanism is probably 5-HT antagonism. This hypothesis was supported when researchers combined typical antipsychotics with a 5-HT₂ antagonist like ritanserin [28-31]. When used in combination they resulted in substantial relief of patients' negative symptoms and motoric side effects. The theory of a 5-HT-dopamine interaction as the mechanism behind schizophrenia is beginning to gain wide acceptance. However, the exact role of 5-HT is still not clear. Its effects on dopamine aside, 5-HT has a great deal of direct inhibitory effect on prefrontal neurons. One cannot ignore the possible role of such actions on schizophrenia and further investigation is warranted [32, 33].

OTHER RECEPTORS

Line of evidence has been accumulating that implicates the involvement of cholecystokinin, neurotensin, glutamate,

α 2-adrenoceptor, and other receptor systems in the pathophysiology of schizophrenia for example, the corticostriatal glutamate pathway may directly or indirectly (*via* γ -aminobutyric acid [GABA]) inhibit dopamine function from the ventral striatum leading to increased inhibitory activity in the limbic system. Therefore, decreased activation of glutamate receptors may increase limbic dopamine release, producing symptoms that parallel the apparent limbic dopaminergic hyperactivity thought to be associated with the positive symptoms of schizophrenia. Adenosine receptors have also been implicated [7]. Studies of the four recently cloned adenosine receptors (A₁, A_{2A}, A_{2B}, A₃) propose that the A_{2A} receptor may have the ability to interact with other neurotransmitter receptors, including the dopamine D₂ receptor. In animal models, the A_{2A} agonist CG21680 (2-(4-[2-carboxyethyl]-phenethylamino) adenosine-5'-*N*-ethyluronamide) appears to have antipsychotic efficacy and, conversely, the adenosine competitive antagonist caffeine potentiates behavioral effects similar to a dopamine agonist. A modulation of dopamine D₂ receptors by adenosine A₂ receptors in the ventral striatum has been proposed and supported by few clinical trials [7, 24].

PHARMACOTHERAPY OF SCHIZOPHRENIA

The 1990s could justifiably be seen as the decade of psychopharmacology. Since 1990, five new antipsychotics have been approved for use in the USA: risperidone, olanzapine, sertindole (subsequently withdrawn), quetiapine and ziprasidone. These antipsychotics, along with the prototypical drug clozapine, are all considered atypical [32-36].

WHY ATYPICAL ANTIPSYCHOTICS?

The outcome for many schizophrenic patients treated with conventional antipsychotics is unsatisfactory. Most controlled trials continue to find a subgroup of 10 to 20% of patients who derive little benefit from typical antipsychotic therapy [7]. Moreover, there is 20 to 30% relapse during the first two years of drug treatment in patients who are initially responsive to antipsychotic drugs [7]. Classical antipsychotic drug treatment appears to have little effect on either the chronic course of the illness or negative symptoms. The negative symptoms tend to be persistent, disabling, difficult to treat and prognostically unfavorable [37-40]. The adverse effects associated with conventional antipsychotics, in particular extrapyramidal adverse effects, can result in poor compliance [37, 38].

THE TREATMENT OF SCHIZOPHRENIA

Modern treatment for schizophrenia relies primarily on somatic drug therapy. Pharmacological treatment for schizophrenia did not begin until approximately a century ago [18, 20]. Before this, beliefs surrounding all mental illness were grounded in religious dogma and it was not until the 19th century that any substantial advances were made. Drugs from the phenothiazine class were originally used as anthelmintics in veterinary medicine, but in 1950 in Paris, Paul Charpentier synthesized chlorpromazine, a mild antihistamine that appeared notable as a sedative agent and revolutionized psychiatric treatment. In 1952, Jean Delay and Pierre Deniker reported that chlorpromazine was

effective in treating patients with acute psychosis [18, 20] while in 1954 in Montreal, Heinz Lehmann reported the successful use of the drug in the treatment of schizophrenia. Chlorpromazine, which is still widely used today, was administered for the next 14 years despite there being little understanding of how or why it worked. Currently two categories of antipsychotics are in common use: typical and atypical antipsychotics [20, 37-39]. The former class, which represents the first antipsychotics to reach mainstream use, act primarily on the brain's dopaminergic pathways and show very little regional specificity. Typical antipsychotics are usually effective in controlling the positive symptoms of the illness but are associated with potential complications like neuroleptic malignant syndrome or extrapyramidal side effects and the long-term problem, tardive dyskinesia. Today they are still in common use, but over last few years their dominant position in the treatment of schizophrenia has diminished, as newer, atypical antipsychotic drugs have been developed [18, 20, 37-39]. One of the most common and most potent typical antipsychotics in current use is haloperidol, which is thought to work by blocking dopaminergic neurotransmission in the mesolimbic tract. Dopaminergic pathways in this area are thought to be involved in arousal, memory, stimulus processing, locomotor activity and motivational behavior [40, 41]. Hyperactivity in the mesolimbic tract causes overexcitation of different processes and is associated with the positive symptoms of schizophrenia [4]. Haloperidol, along with other typical antipsychotics is unfortunately not very selective in which dopaminergic pathways it antagonizes [40, 41]. This can lead to unwanted reactions in the mesocortical tract and nigrostriatal pathways. The mesocortical tract projects into the prefrontal and frontal cortices [42]. This system has been implicated in cognition, communication and social activity impairment. Diminished dopamine activity has been observed in numerous schizophrenia studies and it is thought to be responsible for degradation in mesocortical activity [5]. As a result, reduced levels of dopamine are believed to be the primary cause of the negative symptoms of schizophrenia. For these reasons, haloperidol, which reduces dopamine levels even further, is relatively ineffective in relieving negative symptoms and at high doses can even lead to exacerbation of these symptoms [43, 44].

The newest category of medication used in the treatment of schizophrenia are the dopamine receptor antagonists (typical antipsychotics) and the serotonin-dopamine antagonists (SDAs) (also called newer, novel, or atypical antipsychotics). Differentiating the two classes of antipsychotics-dopamine receptor antagonists and SDAs-is increasingly important, since they have different mechanisms of action and different clinical effects [45-48]. Clozapine is a heterocyclic benzodiazepine derivative [34], which was one of the first antipsychotics to demonstrate only limited extrapyramidal side effects. Its D_1 and D_2 receptor antagonism affinities are low [37, 38] and unlike typical antipsychotics, clozapine has a regional specificity for mesolimbic dopamine tracts, with only weak affinities for striatal D_2 receptors. This regional specificity allows clozapine, and other atypical antipsychotics, to act upon the mesolimbic-induced positive symptoms without creating major side effects. The drug does not block behaviors

induced by amphetamine or apomorphine, further suggesting that any dopamine antagonism is secondary to other activities. The antipsychotic effects of clozapine seem to result in the lessening of both positive and negative symptoms (mainly secondary negative symptoms), without the system-degenerating side effects. It appears to have an acute, clearly dose-dependent effect on the aggressive behavior associated with schizophrenia [49-51]. However, even clozapine has unwanted side effects, which have necessitated discontinuation of clozapine therapy in 8% of patients. The most serious side effect, agranulocytosis, is characterized by an abnormally low granulocyte or total white blood cell count [52]. Although clozapine has proven extremely successful as an antipsychotic, it cannot be employed to treat schizophrenia until two antipsychotics have failed to produce significant results [53]. This fact is almost directly due to the risk of agranulocytosis [53, 54].

Risperidone is the second atypical antipsychotic to come into common use. Unlike clozapine it can be used as a first line therapy against schizophrenia and is in widespread use. It acts upon the same receptor sites as clozapine with some extra affinities for benzodiazepine receptors, 5-HT₁ receptors, α_2 -adrenergic and β -adrenergic receptors [36-38] and appears to reduce both positive and negative symptoms with the same efficacy. The side effect profile of the drug is similar to clozapine, but the risk of extrapyramidal adverse effects appears higher and no case of agranulocytosis has ever been recorded. Its more frequent prescription rate appears to be due to this lessened side effect risk and its lower cost [36-38].

Olanzapine is third FDA approved atypical antipsychotic. Its efficacy seems to match clozapine and risperidone, while its side effect profile is identical to risperidone. Olanzapine specifically blocks 5-HT and D₂ receptors and additionally blocks muscarinic (M_1), H₁, 5-HT_{2c}, 5-HT₃, 5-HT₆, α_1 , D₁ and D₄ receptors. Its 5-HT blockade is about 8-fold stronger than its dopamine receptor blockade [36-38]. Somnolence, dry mouth, dizziness, constipation, dyspepsia, increased appetite, and tremor are associated with olanzapine use. Olanzapine is somewhat more likely than risperidone to cause weight gain. Two percent of patients may need to discontinue use of the drug because of transaminase elevation [36-38].

Amisulpride is a selective dopamine D₂/D₃ receptor blocker. The evaluation of this atypical antipsychotic specifically addressed the question of efficacy in negative symptoms [46]. Although amisulpride is not a serotonin-dopamine antagonist, it is not associated with extrapyramidal symptoms. Their exact mechanism of low EPS is not clear but is hypothesized to be a preference for mesolimbic over nigrostriatal dopamine receptors in animal models [46].

Ziprasidone is an antagonist of 5-HT_{1D}, 5-HT_{2A}, and 5-HT_{2C}; D₂, D₃ and α_1 receptors. Ziprasidone also has agonist activity at serotonin 5-HT_{1A} receptors and is a serotonin reuptake inhibitor and a norepinephrine reuptake inhibitor. The most common adverse effects in patients taking ziprasidone were somnolence, headache, dizziness, nausea and QT prolongation in patients with a history of cardiac arrhythmia [46].

Quetiapine is an antagonist of 5-HT₂ and 5-HT₆, D₁ and D₂, H₁ and α ₁ and α ₂ receptors. It does not block muscarinic or benzodiazepine receptors. Quetiapine like clozapine is not associated with extrapyramidal symptoms. The most common adverse effects of quetiapine are somnolence, postural hypotension and dizziness [55, 56].

Aripiprazole is the newest atypical antipsychotic to come into practice. It is a unique antipsychotic that exhibits partial agonism at the dopamine D₂ and serotonin 5HT_{1A} receptors and antagonism at the serotonin 5HT_{2A} receptors. Aripiprazole also displays a high affinity for dopamine D₂ and D₃, serotonin 5HT_{1A} and 5HT_{2A} receptors, moderate affinity for dopamine D₄, serotonin 5HT_{2C} and 5HT₇, α ₁ adrenergic and histamine H₁ receptors, and moderate affinity for the serotonin reuptake site. Aripiprazole lacks affinity for the cholinergic muscarinic receptors [57, 58]. Aripiprazole is contraindicated in patients with a known hypersensitivity to the product. The risk of neuroleptic malignant syndrome is limited, but still present, with aripiprazole administration. It may be associated with orthostatic hypotension and should be used with caution among patients with cardiovascular or cerebrovascular disease or conditions that predispose patients to hypotension [57, 58]. Aripiprazole should be used with caution among patients with a history of seizures or with conditions that lower the seizure threshold. The risk of seizures in preliminary, short term, placebo controlled studies is very low to absent (1/926 or 0.1%) [57, 58].

The safety and efficacy of aripiprazole has not been established among pregnant or breastfeeding women and should be used only if the potential benefits outweigh the risks associated with its use. In addition, the safety and efficacy of aripiprazole has not been established among pediatric and adolescent patients [57, 58].

The incidence of EPS was the same for the aripiprazole and placebo groups at 6%. There were no significant changes in routine serum chemistry, hematology, electrocardiogram or urine analysis measures. There was a slight difference in mean weight gain between aripiprazole and placebo patients [57, 58].

EMERGING ADVERSE EFFECTS OF THE ATYPICALS

In reviewing research with the atypical antipsychotics over the last 10 years, long-term side effects of these medications are emerging. Reports about endocrine and metabolic side effects such as hyperprolactinemia, weight gain, obesity, dyslipidemias, diabetes, and cardiac adverse effects are becoming a serious cause for concern [59-62].

DYSLIPIDEMIA

Concerns about hyper triglyceridemia and antipsychotic use were raised first in 1995. Clozapine has been linked to an increased risk of hyper triglyceridemia and dyslipidemias [59-61]. Among 82 patients in a 5-year naturalistic study, those treated with clozapine for 1 year gained more than 40% of their body weight and had significantly increased serum triglycerides during the 60-month trial period [59-61]. Other reports have documented a mean increase in fasting

serum triglycerides of 60 to 70 mg/dL associated with both short- and long-term olanzapine treatment. While modest triglyceride increases were described with early typicals, the large increases seen with clozapine-, olanzapine-, and quetiapine-treated patients are likely related to the distinct pharmacology of the atypicals. Cases of severe hyperlipidemia have been reported among most atypicals, except for risperidone. In a study of 4 clozapine-treated patients with hypertriglyceridemia, it was reported that the triglycerides normalized after switching to risperidone [59-61]. Patients with elevated triglycerides are at risk for acute pancreatitis and long-term cardiovascular morbidity [59-61].

HYPERGLYCEMIA OR DIABETES MELLITUS

Reports of new-onset diabetes and diabetic ketoacidosis in patients treated with clozapine, olanzapine (28-30), and quetiapine [60] continue to accumulate. Among 82 patients treated with clozapine in a 5-year naturalistic study, 37% were diagnosed with adult-onset diabetes, and 72% of them went on to require oral hypoglycemic agents or insulin therapy for their glucose dysregulation [60]. Since 1994, most studies of the emergence of hyperglycemia and diabetes during treatment with atypical antipsychotics involved clozapine (n = 20), followed by olanzapine (n = 13), quetiapine (n = 3) and risperidone (n = 4). Most frequently, hyperglycemia was not dosage-dependent and was reversible with cessation of treatment with olanzapine and clozapine but reappeared after reintroduction of the drug [60]. Schizophrenia is a known risk factor for adult-onset diabetes mellitus [60]. Therefore, the risk is enhanced with neuroleptics, particularly olanzapine and clozapine, but also with some low-potency conventional neuroleptics. Diabetes-associated morbidity includes such problems as cardiovascular disease, cerebrovascular disease, and renal disease and leads to a significant increased risk of mortality [60]. Ziprasidone and aripiprazole appear to be associated with a relatively low risk for hyperlipidemia and are relatively weight neutral [61].

ISSUE WITH GENERAL SCHIZOPHRENIA RESEARCH

Still, there is a great deal of suspicion where schizophrenia treatment is concerned. There is not as of yet a clear understanding of what schizophrenia is and how it works. A large number of patients still do not respond adequately to medication. Clozapine was a previously forgotten medicine that was reintroduced when it was found how to prevent agranulocytosis. Risperidone and olanzapine were descendants of clozapine that had no potential for causing agranulocytosis. These medications were introduced quickly in the late 1980's and early 1990's as alternatives to conventional neuroleptics. It is regularly accepted that these medications have a lower chance of causing extrapyramidal symptoms. The research generally compares these medications to haloperidol, which generally has the highest likelihood of causing these symptoms, rather than chlorpromazine, which is more commonly used. Psychiatric research is supposed to occur under a double-blind condition, so that neither patient nor doctor is to know who is getting the experimental treatment and who is getting the control treatment. Nevertheless, the sudden occurrence of

extrapyramidal effects in the patients receiving haloperidol makes it immediately clear which is the control group and which is the experimental group [63].

The aspect of schizophrenia most closely studied is symptomology, and to a far lesser extent, behavior resulting from psychiatric symptomology. Yet, the most important aspect of a deinstitutionalized schizophrenic's life is the ability to function socially. This aspect is almost never researched. There is some concern that the atypical neuroleptics may not be safe for long-term use, and some reports that extrapyramidal effects do eventually occur with long-term use [64]. Novel neurotransmitter mechanisms other than serotonin and dopamine for therapeutic strategies in schizophrenia beyond positive symptoms are important research issues for psychopharmacologists. Several recent studies have indicated promising results with neurotensin antagonists, purinergic agents, alpha-7-nicotinic cholinergic agonists and glutamatergic compounds [65]. Rapidly advancing research into schizophrenia includes diverse etiological hypotheses, and offers directions for future research and treatments.

CONCLUSION

Schizophrenia is clinically heterogeneous and is believed to be the common syndrome resulting from a number of different etiopathogenic processes. The advent of the novel antipsychotics during the last 15 years represents a significant improvement over the effectiveness of conventional antipsychotics. However, these agents are not a magic bullet and are associated with their own attendant treatment complications. For all of these reasons, advances in the treatment of schizophrenia have been and continue to be urgently needed.

ACKNOWLEDGEMENTS

I dedicate this review article to Professor Sh. Tarighati, one of the pioneers of modern psychiatry in Iran for 40 years invaluable services to higher education of Iran.

REFERENCES

- [1] Baron M, Gruen R, Rainer JD: A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia. *Am. J. Psychiat.* 1985; 142: 447-55.
- [2] Jablensky A, Sartorius N, Ernberg G: Schizophrenia: manifestation, incidence and course in different cultures. A World Health Organization ten-country study. *Psychological Med.* 1991; 20(suppl): 1-97.
- [3] Nestler EJ: Schizophrenia: an emerging pathophysiology. *Nature.* 1997; 385: 578-579.
- [4] Wright I, Woodruff P: Aetiology of schizophrenia. Review of theories and their clinical and therapeutic implications. *CNS Drugs.* 1995; 3: 126-144.
- [5] Akhondzadeh S: The glutamate hypothesis of schizophrenia. *J. Clin. Pharm. Ther.* 1998; 23: 243-246.
- [6] Mohammadi MR, Akhondzadeh S: Schizophrenia: Etiology and pharmacotherapy. *IDrugs.* 2001; 4: 1167-1172.
- [7] American Psychiatric Association: Diagnostic and statistical manual of mental disorders, fourth ed. Washington DC: American Psychiatric Association. 1994.
- [8] Anderson NC, Olsen SA: Negative vs. positive schizophrenia: Definition and validation. *Arch. Gen. Psychiat.* 1989; 39: 789-794.
- [9] Arndt S, Allinger RJ, Anderson NC: The distinction of positive and negative symptoms. The failure of a two dimensional model. *Br. J. Psychiat.* 1991; 158: 317-322.
- [10] Heyman I, Murray RM: Schizophrenia and neurodevelopment. *J. R. Col. Physicians Lond.* 1992; 26: 143-146.
- [11] Kendler KS, Diehl SR: The genetics of schizophrenia: a current genetic-epidemiologic perspective. *Schizophrenia Bull.* 1993; 19: 261-285.
- [12] Littrel RA, Schneiderhan M: The Neurobiology of Schizophrenia. *Pharmacotherapy.* 1996; 16: 143S-147S.
- [13] Snyder S: The dopamine hypothesis in schizophrenia: focus on the dopamine receptor. *Am. J. Psychiat.* 1976; 133: 197-202.
- [14] Johnstone E, Crow T, Frith C: Mechanism of antipsychotic effect in the treatment of acute schizophrenia. *Lancet.* 1978; 1: 848-51.
- [15] Darlsson A: The current status of the dopamine hypothesis of schizophrenia. *Neuropsychopharmacol.* 1988; 1: 179-86.
- [16] Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. *Am. J. Psychiat.* 1991; 148:1474-86.
- [17] Breier A, Wolkowitz OM, Doran AR: Neuroleptic responsiveness of negative and positive symptoms in schizophrenia. *Am. J. Psychiat.* 1987; 144: 1549-1555.
- [18] Meltzer HY, Lee MA, Ranjan, R: Recent advances in the pharmacotherapy of schizophrenia: *Acta. Psychiat. Scand.* 1994; 90 (suppl): 95-101.
- [19] Akhondzadeh S, Mohammadi MA, Amini-Nooshabadi H, Davari-Ashtiani: Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. *J. Clin. Pharm. Ther.* 1999; 24: 49-52.
- [20] Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H: Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. *J. Clin. Pharm. Ther.* 1999; 24: 369-374.
- [21] Akhondzadeh S, Shasavand E, Jamilian HR, Shabestari O, Kamalipour A: Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. *J. Clin. Pharm. Ther.* 2000; , 25, 131-137.
- [22] Anderson NC: schizophrenia: the fundamental questions. *Brain Res. Reviews.* 2000; 31: 106-112.
- [23] Akhondzadeh S, Safarcherati A, Amini H: Beneficial antipsychotic effects of allopurinol as adjunctive therapy for schizophrenia: A double blind, randomized and placebo controlled trial. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2005; 29: 253-259.
- [24] Claridge G: LSD: A missed opportunity. *Human Psychopharmacol.* 1994; 9: 343-351.
- [25] Awouters FHL, Niemegeers CJE, Megens AAAHP: Functional interaction between serotonin S2 and dopamine D2 neurotransmission as revealed by selective antagonism of hyperactivity to tryptamine and apomorphine. *J. Pharm. Exp. Therapeutics.* 1990; 254: 945-951.
- [26] Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S: Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. *Eur. Arch. Psychiat. Clin. Neurosci.* 1999; 249: 83-9.
- [27] Abi-Dargham A, Laruelle, M, Aghajanian GK, Charney D, Krystal J: The role of serotonin in pathophysiology and treatment of schizophrenia. *J. Neuropsychiatry Clin. Neurosci.* 1997; 9: 1-17.
- [28] Busatto GF, Kerwin RW: Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. *J. Psychopharmacol.* 1997; 11: 3-12.
- [29] Darlsson A, Waters N, Darlsson ML: Neurotransmitter interactions in schizophrenia-therapeutic implications. *Biol. Psychiat.* 1999; 15: 1388-95.
- [30] Richelson E: Receptor Pharmacology of Neuroleptics: relation to clinical effects. *J. Clin. Psychiatry* 1999; 60: 5-14.
- [31] Lieberman JA, Mailman RB, Duncan G, *et al.* Serotonergic basis of antipsychotic drug effects in schizophrenia. *Biol. Psychiat.* 1998; 44: 1099-1117.
- [32] Meltzer HY: The role of serotonin in antipsychotic drug action. *Neuropsychopharmacol.* 1999; 21 suppl: 106-115.
- [33] Breier A, Buchanan RW, Kirkpatrick B: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. *Am. J. Psychiat.* 1990; 151: 20-26.
- [34] Breier A, Kirkpatrick B, Buchanan RW: Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. *Biol. Psychiat.* 1993; 34: 492-494.

- [36] Meltzer HY: The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. *J Clin Psychopharmacol.* 1995; 15: 2S-3S.
- [37] Meltzer HY: The role of serotonin in Antipsychotic Drug Actions. *Neuropsychopharmacol.* 1999; 21: 106-115.
- [38] Stahl SM: What makes an antipsychotic atypical. *J. Clin. Psychiat.* 1999; 60: 3-4.
- [39] Marder SR: Newer antipsychotics. *Current Opinion in Psychiat.* 2000; 13: 11-14.
- [40] Addington D, Collins EJ, Jones BD, Lalonde P: Current status and role in the pharmacotherapy of schizophrenia. *Canadian J. Psychiat.* 1996; 41: 161-166.
- [41] Bogerts B: Recent advances in the neuropathology of schizophrenia. *Schizophrenia Bull.* 1993; 19: 431-445.
- [42] Owen F, Simpson M: The neurochemistry of schizophrenia. *Mol. Cell Biol. Hum. Dis.* 1994; 4: 133-59.
- [43] Arnold Se, Bordelon Y, Gur RE: Mesolimbic D3 receptors and use of antipsychotics in patients with schizophrenia. *Arch. Gen. Psychiat.* 1997; 54: 225-232.
- [44] Anderson NC: Negative symptoms in schizophrenia: definition and reliability. *Arch. Gen. Psychiat.* 1982; 39: 784-788.
- [45] Meltzer HY, Zureick J: Negative symptoms in schizophrenia: a target for new drug development. 1989 In: *Clinical Pharmacology in Psychiatry*, SG Dahl and LF Gram (Eds), Springer-Verlag, Berlin Heidelberg. 1989; 46-68.
- [46] Moller HJ: Management of the negative symptoms of schizophrenia: new treatment options. *CNS Drugs* 2003; 17:793-823.
- [47] Silver H, Blacker M, Weller MPI, Lerer B: Treatment of chronic schizophrenia with cyproheptadine. *Biol. Psychiat.* 1989; 25: 502-4.
- [48] Breier A: Serotonin, schizophrenia and antipsychotic drug action. *Schizophrenia Res.* 1995; 14: 187-202.
- [49] Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. *Am. J. Psychiat.* 1996; 153: 466-76.
- [50] Arota RC, Meltzer HY: Serotonin₂ (5-HT₂) receptor binding in the frontal cortex of schizophrenic patients. *J. Neural. Transm. Gen. Sec.* 1991; 85: 19-29.
- [51] Nordstrom AL, Farde L, Halldin C: 5-HT₂ receptor occupancy in clozapine-treated patients demonstrated by PET. *Psychopharmacol.* 1993; 110: 365-367.
- [52] Kinon BJ, Liberman JA: Mechanisms of action of atypical antipsychotic drugs: a critical analysis. *Psychopharmacol.* 1996; 124: 2-34.
- [53] Honigfeld G, Arellano F, Sethi J: Reducing clozapine-related morbidity and mortality: 5 years of experience with Clozaril National Registry. *J. Clin. Psychiat.* 1998; 59: 3-7.
- [54] Conley RR: Optimizing treatment with clozapine. *J. Clin. Psychiat.* 1998; 59: 44-48.
- [55] Buckley PF: Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. *Curr. Med. Res. Opin.* 2004; 20: 1357-63.
- [56] Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. *Hum. Psychopharmacol.* 2004; 19: 559-63.
- [57] Kane JM, Carson WH, Anutosh RS, McQuade RD, Ingenito GG, Zimbroff DL: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. *J. Clin. Psychiatry* 2002; 63: 763-71.
- [58] Travis MJ, Burns T, Dursun S, *et al.* Aripiprazole in schizophrenia: consensus guidelines. *Int. J. Clin. Pract.* 2005; 59: 485-95.
- [59] Osseer DO, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglycerides. *J. Clin. Psychiatry* 1999; 60: 767-70.
- [60] Henderson DC, Cagliero E, Gray C, *et al.* Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. *Am. J. Psychiatry* 2000; 157: 975-81.
- [61] Koro CE, Meyer JM: Atypical antipsychotic therapy and hyperlipidemia: a review. *Essent. Psychopharmacol.* 2005; 6:148-57.
- [62] Macguire GA: Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. *J. Clin. Psychiatry* 2002; 63: 56-62.
- [63] Lindenmayer JP, Khan A: Pharmacological treatment strategies for schizophrenia. *Expert Rev. Neurother.* 2004; 4: 705-23.
- [64] Pierre JM: Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. *Drug Saf.* 2005; 28: 191-208.
- [65] Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. *Mol. Interv.* 2003; 3: 27-39.